ClinicalTrials.gg
Not yet recruitingNCT06900192Updated Nov 13, 2026

A Multicenter Phase 1 Study of Orca-Q in Primary Progressive Multiple Sclerosis

A Phase 1 interventional study of Orca-Q and myeloablative regimen in Primary Progressive Multiple Sclerosis, Multiple Sclerosis and Multiple Sclerosis, Primary Progressive, sponsored by Orca Biosystems, Inc.. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Orca Biosystems, Inc. · Phase 1, Interventional, and Treatment

How we know

Updated Nov 13, 2026Start date movedPrimary completion moved+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

A study of allogeneic hematopoietic cell transplantation (alloHCT) with Orca-Q for the treatment of primary progressive multiple sclerosis (PPMS).

Read the detailed description

This study will evaluate alloHCT with Orca-Q, an allogeneic hematopoietic graft isolated from a donor's hematopoietic cells for the treatment of PPMS.

02

Conditions studied

  • Primary Progressive Multiple Sclerosis
  • Multiple Sclerosis
  • Multiple Sclerosis, Primary Progressive

Keywords

  • Orca-Q
03

In context

Multiple Sclerosis, Chronic Progressive

245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.

This study's planned enrollment of 10 is below the median of 54 across 190 interventional studies indexed under Multiple Sclerosis, Chronic Progressive.

Browse Multiple Sclerosis, Chronic Progressive studies →

Lead sponsor

Orca Biosystems, Inc. is the lead sponsor of 6 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 13, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants aged ≥18 and ≤65 years with PPMS

    a. A diagnosis of PPMS by 2024 McDonald criteria and 2013 clinical course revision

  2. Cerebrospinal fluid (CSF) with elevated IgG index or 2 or more oligoclonal bands
  3. EDSS between 2.0 and 5.5 inclusive
  4. Based on review of the clinical records, there must be a deterioration in the EDSS of at least 1 or more points over the previous 4 years (or less)
  5. Eligibility criteria confirmed by the Eligibility Review Group
  6. Recipients who have been treated with ocrelizumab, rituximab, ofatumumab, ublituximab, or alemtuzumab must undergo a as specified in the protocol prior to their planned day 0
  7. Recipients must be willing to undergo mobilized autologous peripheral blood stem cell collection to create a cryopreserved rescue product prior to alloHCT
  8. Willing to undergo MAC preparative regimen
  9. Matched to either a related or unrelated donor as follows:

    1. Matched related donor who is a 10/10 match for HLA-A, -B, -C, -DRB1 and -DQB1, all typed using DNA-based high-resolution methods
    2. Matched unrelated donor who is a 10/10 match at HLA-A, -B, -C, -DRB1 and -DQB1, all typed using DNA-based high-resolution methods
  10. Negative serum or urine β-HCG test in persons of

Exclusion criteria

Exclusion Criteria:

  1. History of Progressive Multifocal Leukoencephalopathy
  2. Organ dysfunction or disease that would jeopardize survival after hematopoietic cell transplantation, including but not limited to the following:

    1. Renal insufficiency as defined by an estimated \<60 mL/minute
    2. Cardiac dysfunction as defined by symptomatic coronary artery disease, congestive heart failure, valvular heart disease, cardiomyopathy, uncontrolled arrhythmia(s), or \<50%. Participants with a history of these conditions may enroll if they are demonstrated to have optimal cardiac function (as defined by echocardiography or multi-gated acquisition scan)
    3. Pulmonary dysfunction that poses a risk of mortality after transplant, defined as pre-transplant pulmonary function testing demonstrating a \<70% expected and/or a DLCOadj \<70% expected
    4. Necroinflammatory or fibrotic liver disease with evidence of liver dysfunction, including but not limited to jaundice, hepatic encephalopathy, or portal hypertension
    5. Marrow dysfunction that poses a risk of peri-transplant mortality, defined as an (\<1000/mm3) below the lower limit of normal, or a count below 50,000/mm3
    6. Poorly controlled hypertension despite appropriate therapy, defined as a diastolic blood pressure greater than 90 mm Hg while on therapy
    7. Poorly controlled diabetes mellitus, defined as HgbA1c ≥ 6.5% despite therapy or recurrent hypoglycemia while on therapy
    8. Extreme protein-calorie malnutrition defined by \<18 and unintentional weight loss (3 kg in the last month or 6 kg in the last 6 months.)
  3. History of smoking either tobacco or other herbal products in the last 3 months
  4. Planned pharmaceutical in vivo or ex vivo T cell depletion (TCD), (eg, cladribine, or peritransplant antithymocyte globulin [ATG]). For participants who have previously been exposed to a TCD agent, a 5-half-life washout of the agent must occur prior to planned day 0 (day 0 is defined as the day of Orca-Q infusion). The for alemtuzumab is specified in the protocol
  5. seropositive
  6. serology results indicating chronic HBV infection per https://www.cdc.gov/hepatitis/hbv/interpretationOfHepBSerologicResults.htm, unless HBV PCR negative. HBV seropositive participants should be on antiviral therapy after transplant
  7. seropositive, unless PCR negative and having undergone 'curative' antiviral therapy
  8. Participant has active uncontrolled infection
  9. Participant has demonstrated lack of compliance with prior medical care
  10. Participants with known active . It is recommended that patients are current on cancer screening tests for their age and family history as per the NCCN [The National Comprehensive Cancer Network®] Guidelines. Screening should be performed, if indicated, per NCCN guidelines prior to study treatment.
  11. Participants whose is severely limited by illness other than multiple sclerosis
  12. Females who are pregnant or breast feeding
  13. Medical or psychiatric conditions that compromise ability to give or to comply with treatment protocol
  14. Inability to undergo an MRI scan
  15. Currently receiving treatment with agents
  16. Positive for JC virus DNA in the CSF or blood during screening
  17. Known allergy or to or intolerance of tacrolimus
  18. Documented allergy or hypersensitivity to iron dextran or bovine, murine, algal, or Streptomyces avidinii proteins
  19. Recipient-positive antidonor HLA antibodies against a mismatched allele in the selected donor determined by either of the following:

    1. Positive crossmatch test of any titer (by complement-dependent cytotoxicity or flow cytometric testing) to any of the following HLA loci (if mismatched): HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1, HLA-DQA1, HLA-DPB1, or HLA-DPA1
    2. Presence of antidonor HLA antibody to any of the following HLA loci (if mismatched): HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQA1, or HLA-DPB1, with mean fluorescence intensity ≥1000 by solid phase immunoassay
  20. People of (POCBP) or men who have sexual contact with POCBP who are unwilling to use effective forms of or abstinence for 1 year after transplantation
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Orca-Q Graft with myeloablative conditioning regimen

    Donor Orca-Q stem cell graft

    Biological: Orca-Q · Drug: myeloablative regimen · Drug: Tacrolimus

Interventions

06

What researchers measure

Primary outcomes

  1. Severe acute graft-versus-host-disease-free survival

    Number of participants who are alive without a history of grade ≥3 (severe) acute graft-versus-host disease (aGVHD), graded per Mount Sinai Acute GVHD International Consortium (MAGIC) criteria (range: grades 0-4 with higher number being worse)

    Time frame: Up to 6 months after infusion

Secondary outcomes

  1. Event-Free Survival (EFS)

    Participant is alive and free of PPMS progression. An event is defined as sustained loss of neurological function (Expanded Disability Status Scale \[EDSS, range of 0-10 with higher numbers being worse\] increase \>1 point sustained for 3 months), relapse, one or more new or enlarging MRI lesions, or death

    Time frame: Up to 24 months and at year 5 after Orca-Q infusion

  2. Loss of Neurological Function or Relapse

    Assessment of sustained neurological worsening as measured by EDSS (\>1-point increase) or occurrence of PPMS relapse. EDSS spans the range of 0-10 with higher numbers being worse

    Time frame: Every 3 months through Month 12 and every 6 months from Months 13-24 after transplant

  3. Overall Survival (OS)

    Time in years from transplant to death from any cause

    Time frame: From transplant through 5 years after transplant

  4. Treatment-Related Mortality (TRM)

    Death definitely or probably resulting from study treatment and not attributable to other causes, as determined by review of clinical and autopsy data

    Time frame: From start of alloHCT through 5 years after transplant

  5. Incidence of Disease-Modifying Therapy Use for PPMS After Orca-Q

    Number of participants with initiation or re-initiation of disease-modifying therapy for PPMS following Orca-Q infusion. Use of therapies for GVHD or other transplant-related conditions is excluded

    Time frame: From Orca-Q infusion through 5 years after transplant

  6. Incidence of aGVHD

    Number of participants with aGVHD

    Time frame: From transplant through 5 years after transplant

  7. Severity of aGVHD

    Severity is graded per MAGIC criteria

    Time frame: From transplant through 5 years after transplant

  8. Incidence chronic graft-versus-host disease (cGVHD)

    Number of participants with cGVHD

    Time frame: From transplant through 5 years after transplant

  9. Severity of cGVHD

    cGVHD severity will be categorized using NIH global severity scores of mild, moderate, and severe cGVHD

    Time frame: From transplant through 5 years after transplant

  10. Incidence of Primary Graft Failure

    Number of participants alive without recovery of neutrophils \[ie, without achieving an abosolute neutrophil count (ANC) ≥500/mm3 for 3 consecutive days\] at day +28 without another identifiable cause

    Time frame: Through day +28

  11. Incidence of Secondary Graft Failure

    Number of participants with neutrophil engraftment followed by subsequent decline in ANC \<500/mm3, unresponsive to growth factor therapy, by day +100 without another identifiable cause

    Time frame: Through day +100

  12. Time to Neutrophil Engraftment

    Neutrophil engraftment is defined as an absolute neutrophil count (ANC) of 500 or more neutrophils per μL blood, sustained for 3 days in a row. The day of neutrophil engraftment is defined as the first day of ANC ≥ 500/μL. Time to neutrophil engraftment is measured in days.

    Time frame: From transplant through Day +365

  13. Development of Infectious Complications

    Incidence of definite and probable viral, fungal, and bacterial infections occurring after transplantation

    Time frame: From transplant through Day +730 (2 years), with long-term follow-up through 5 years

  14. Regimen-Related Toxicity

    Number of participants with regimen-related toxicities (adverse events attributed to the conditioning regimen, Orca-Q, or GVHD prophylaxis), graded per the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 6.0 (range: Grade 1-5, with higher grades being worse).

    Time frame: From start of conditioning through 1 year after transplant

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2027; primary completion for Jun 2028, 15 months later.

Of 21 phase 1 interventional studies under Multiple Sclerosis, Chronic Progressive, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 15 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: start Mar 2025 → Mar 2027, primary completion Aug 2029 → Jun 2028 and completion Aug 2029 → Dec 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2025
First posted
Mar 28, 2025
StartEst.
Mar 2027was Mar 2025
Primary completionEst.
Jun 2028was Aug 2029
CompletionEst.
Dec 2032was Aug 2029
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Mar 2025→Mar 2027
Nov 13, 2026
Primary completion
Aug 2029→Jun 2028
Nov 13, 2026
Study completion
Aug 2029→Dec 2032
Nov 13, 2026
Eligibility
6 inclusion criteria edited, 5 added, 3 removed; 1 exclusion criterion edited, 6 added
What changed in the criteria
Inclusion criteria
  • EditedParticipants aged ≥18 and ≤65 years with primary progressive multiple sclerosisPPMS
  • EditedA diagnosis of PPMS by 20172024 McDonald criteria and 2013 clinical course revision102revision
  • EditedCerebrospinal fluid (CSF) with elevated IgG index or 2 or more oligoclonal bands
  • EditedEDSS (see Appendix 9) between 2.0 and 5.5 inclusive
  • EditedEligibility criteria confirmed by the Eligibility Review Group (Appendix 10)
  • EditedRecipients who have been treated with ocrelizumab, rituximab, ofatumumab, ublituximab, or alemtuzumab must undergo a washout period as describedspecified in Appendix 14the protocol prior to their planned day 0.
  • RemovedAbility to undergo MRI without general anesthesia
  • RemovedAbility to undergo all tests and procedures in the study
  • RemovedPatients who are not vaccinated for COVID-19 must have no symptoms of COVID-19 and have negative testing for COVID-19. For other vaccine-preventable illnesses, it is recommended that patients are current on their vaccination schedule.
  • AddedWilling to undergo MAC preparative regimen
  • AddedMatched to either a related or unrelated donor as follows:
  • AddedMatched related donor who is a 10/10 match for HLA-A, -B, -C, -DRB1 and -DQB1, all typed using DNA-based high-resolution methods
  • AddedMatched unrelated donor who is a 10/10 match at HLA-A, -B, -C, -DRB1 and -DQB1, all typed using DNA-based high-resolution methods
  • AddedNegative serum or urine β-HCG test in persons of childbearing potential
Exclusion criteria
  • EditedPlanned pharmaceutical in vivo or ex vivo T cell depletion (TCD), (eg, cladribine, or peritransplant antithymocyte globulin ([ATG]). For participants who have previously been exposed to a TCD agent, a 5-half-life washout of the agent must occur prior to planned day 0 (day 0 is defined as the day of infusion Orca-Q Primeinfusion). The washout period for alemtuzumab is listedspecified in Appendix 14.the protocol
  • AddedKnown allergy or hypersensitivity to or intolerance of tacrolimus
  • AddedDocumented allergy or hypersensitivity to iron dextran or bovine, murine, algal, or Streptomyces avidinii proteins
  • AddedRecipient-positive antidonor HLA antibodies against a mismatched allele in the selected donor determined by either of the following:
  • AddedPositive crossmatch test of any titer (by complement-dependent cytotoxicity or flow cytometric testing) to any of the following HLA loci (if mismatched): HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1, HLA-DQA1, HLA-DPB1, or HLA-DPA1
  • AddedPresence of antidonor HLA antibody to any of the following HLA loci (if mismatched): HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQA1, or HLA-DPB1, with mean fluorescence intensity ≥1000 by solid phase immunoassay
  • AddedPeople of childbearing potential (POCBP) or men who have sexual contact with POCBP who are unwilling to use effective forms of birth control or abstinence for 1 year after transplantation
Nov 13, 2026
Interventions
Added Drug: Tacrolimus. Arm changed Orca-Q Graft with lymphodepleting conditioning regimen→Orca-Q Graft with myeloablative conditioning regimen
Nov 13, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedSevere acute Graftgraft-versus-Hosthost-Diseasedisease-free survivalTime frame: 365 days after infusion → Up to 6 months after infusion
Nov 13, 2026
Secondary outcomes
14 added, 2 removed
What changed in the outcomes
  • AddedEvent-Free Survival (EFS)Time frame: Up to 24 months and at year 5 after Orca-Q infusion
  • AddedLoss of Neurological Function or RelapseTime frame: Every 3 months through Month 12 and every 6 months from Months 13-24 after transplant
  • AddedOverall Survival (OS)Time frame: From transplant through 5 years after transplant
  • AddedTreatment-Related Mortality (TRM)Time frame: From start of alloHCT through 5 years after transplant
  • AddedIncidence of Disease-Modifying Therapy Use for PPMS After Orca-QTime frame: From Orca-Q infusion through 5 years after transplant
  • AddedIncidence of aGVHDTime frame: From transplant through 5 years after transplant
  • AddedSeverity of aGVHDTime frame: From transplant through 5 years after transplant
  • AddedIncidence chronic graft-versus-host disease (cGVHD)Time frame: From transplant through 5 years after transplant
  • AddedSeverity of cGVHDTime frame: From transplant through 5 years after transplant
  • AddedIncidence of Primary Graft FailureTime frame: Through day +28
  • AddedIncidence of Secondary Graft FailureTime frame: Through day +100
  • AddedTime to Neutrophil EngraftmentTime frame: From transplant through Day +365
  • AddedDevelopment of Infectious ComplicationsTime frame: From transplant through Day +730 (2 years), with long-term follow-up through 5 years
  • AddedRegimen-Related ToxicityTime frame: From start of conditioning through 1 year after transplant
  • RemovedEvaluate treatment responseTime frame: Measurements will be taken at 9 and 12 months after infusion
  • RemovedEvaluate safety of treatmentTime frame: Measured from time of enrollment to end of study participation (from date of consent to month 12).
Nov 13, 2026
Contact
Study contact changed: n•••@stanford.edu · •••5522→i•••@orcabio.com · •••9601. See the current contact
Nov 13, 2026
Title
A Multicenter Phase 1 Study of Allogeneic Hematopoietic Cell Transplantation forOrca-Q in Primary Progressive Multiple Sclerosis
Nov 13, 2026
Sponsor
Stanford University→Orca Biosystems, Inc.
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Start date Mar 2025→Mar 2027
    Primary completion Aug 2029→Jun 2028
    Study completion Aug 2029→Dec 2032
    Eligibility 6 inclusion criteria edited, 5 added, 3 removed; 1 exclusion criterion edited, 6 added
    What changed in the criteria
    Inclusion criteria
    • EditedParticipants aged ≥18 and ≤65 years with primary progressive multiple sclerosisPPMS
    • EditedA diagnosis of PPMS by 20172024 McDonald criteria and 2013 clinical course revision102revision
    • EditedCerebrospinal fluid (CSF) with elevated IgG index or 2 or more oligoclonal bands
    • EditedEDSS (see Appendix 9) between 2.0 and 5.5 inclusive
    • EditedEligibility criteria confirmed by the Eligibility Review Group (Appendix 10)
    • EditedRecipients who have been treated with ocrelizumab, rituximab, ofatumumab, ublituximab, or alemtuzumab must undergo a washout period as describedspecified in Appendix 14the protocol prior to their planned day 0.
    • RemovedAbility to undergo MRI without general anesthesia
    • RemovedAbility to undergo all tests and procedures in the study
    • RemovedPatients who are not vaccinated for COVID-19 must have no symptoms of COVID-19 and have negative testing for COVID-19. For other vaccine-preventable illnesses, it is recommended that patients are current on their vaccination schedule.
    • AddedWilling to undergo MAC preparative regimen
    • AddedMatched to either a related or unrelated donor as follows:
    • AddedMatched related donor who is a 10/10 match for HLA-A, -B, -C, -DRB1 and -DQB1, all typed using DNA-based high-resolution methods
    • AddedMatched unrelated donor who is a 10/10 match at HLA-A, -B, -C, -DRB1 and -DQB1, all typed using DNA-based high-resolution methods
    • AddedNegative serum or urine β-HCG test in persons of childbearing potential
    Exclusion criteria
    • EditedPlanned pharmaceutical in vivo or ex vivo T cell depletion (TCD), (eg, cladribine, or peritransplant antithymocyte globulin ([ATG]). For participants who have previously been exposed to a TCD agent, a 5-half-life washout of the agent must occur prior to planned day 0 (day 0 is defined as the day of infusion Orca-Q Primeinfusion). The washout period for alemtuzumab is listedspecified in Appendix 14.the protocol
    • AddedKnown allergy or hypersensitivity to or intolerance of tacrolimus
    • AddedDocumented allergy or hypersensitivity to iron dextran or bovine, murine, algal, or Streptomyces avidinii proteins
    • AddedRecipient-positive antidonor HLA antibodies against a mismatched allele in the selected donor determined by either of the following:
    • AddedPositive crossmatch test of any titer (by complement-dependent cytotoxicity or flow cytometric testing) to any of the following HLA loci (if mismatched): HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1, HLA-DQA1, HLA-DPB1, or HLA-DPA1
    • AddedPresence of antidonor HLA antibody to any of the following HLA loci (if mismatched): HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQA1, or HLA-DPB1, with mean fluorescence intensity ≥1000 by solid phase immunoassay
    • AddedPeople of childbearing potential (POCBP) or men who have sexual contact with POCBP who are unwilling to use effective forms of birth control or abstinence for 1 year after transplantation
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedSevere acute Graftgraft-versus-Hosthost-Diseasedisease-free survivalTime frame: 365 days after infusion → Up to 6 months after infusion
    Secondary outcomes 14 added, 2 removed
    What changed in the outcomes
    • AddedEvent-Free Survival (EFS)Time frame: Up to 24 months and at year 5 after Orca-Q infusion
    • AddedLoss of Neurological Function or RelapseTime frame: Every 3 months through Month 12 and every 6 months from Months 13-24 after transplant
    • AddedOverall Survival (OS)Time frame: From transplant through 5 years after transplant
    • AddedTreatment-Related Mortality (TRM)Time frame: From start of alloHCT through 5 years after transplant
    • AddedIncidence of Disease-Modifying Therapy Use for PPMS After Orca-QTime frame: From Orca-Q infusion through 5 years after transplant
    • AddedIncidence of aGVHDTime frame: From transplant through 5 years after transplant
    • AddedSeverity of aGVHDTime frame: From transplant through 5 years after transplant
    • AddedIncidence chronic graft-versus-host disease (cGVHD)Time frame: From transplant through 5 years after transplant
    • AddedSeverity of cGVHDTime frame: From transplant through 5 years after transplant
    • AddedIncidence of Primary Graft FailureTime frame: Through day +28
    • AddedIncidence of Secondary Graft FailureTime frame: Through day +100
    • AddedTime to Neutrophil EngraftmentTime frame: From transplant through Day +365
    • AddedDevelopment of Infectious ComplicationsTime frame: From transplant through Day +730 (2 years), with long-term follow-up through 5 years
    • AddedRegimen-Related ToxicityTime frame: From start of conditioning through 1 year after transplant
    • RemovedEvaluate treatment responseTime frame: Measurements will be taken at 9 and 12 months after infusion
    • RemovedEvaluate safety of treatmentTime frame: Measured from time of enrollment to end of study participation (from date of consent to month 12).
    Interventions Added Drug: Tacrolimus. Arm changed Orca-Q Graft with lymphodepleting conditioning regimen→Orca-Q Graft with myeloablative conditioning regimen
    Sponsor Stanford University→Orca Biosystems, Inc.
    Contact Study contact changed: n•••@stanford.edu · •••5522→i•••@orcabio.com · •••9601. See the current contact
    Title A Multicenter Phase 1 Study of Allogeneic Hematopoietic Cell Transplantation forOrca-Q in Primary Progressive Multiple Sclerosis
    + 6 other changes: index terms, verification date, oversight details, description, conditions and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06900192
Lead sponsor
Orca Biosystems, Inc.
Responsible party
Sponsor
First posted
Mar 28, 2025
Start date
Mar 2027 (estimated)
Primary completion
Jun 2028 (estimated)
Completion
Dec 2032 (estimated)
Last update
Nov 13, 2026

Study contacts

James S. McClellan, MD, PhD
Contact
info@orcabio.com
650-246-9601

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Allogeneic Defined Hematopoietic Stem Cells/Immune Cells

Start the discussion